Cargando…
Management of rheumatic complications of immune checkpoint inhibitor therapy – an oncological perspective
Immune checkpoint inhibitors (CPIs) are an effective treatment for many cancers but cause diverse immune-related adverse events (IrAEs). Rheumatological IrAEs include arthralgia, arthritis, tenosynovitis, myositis, polymyalgia rheumatica and sicca syndrome. CPI use can unmask RA as well as causing f...
Autores principales: | Steven, Neil M, Fisher, Benjamin A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900910/ https://www.ncbi.nlm.nih.gov/pubmed/31816079 http://dx.doi.org/10.1093/rheumatology/kez536 |
Ejemplares similares
-
Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy
por: Kostine, Marie, et al.
Publicado: (2019) -
Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy
por: Abdel-Wahab, Noha, et al.
Publicado: (2019) -
Management of rheumatic complications of ICI therapy: a rheumatology viewpoint
por: Leipe, Jan, et al.
Publicado: (2019) -
Rheumatic complications in cancer patients treated with immune checkpoint inhibitors
por: Lee, Kyung-Ann, et al.
Publicado: (2019) -
Management of immune checkpoint inhibitor‐related rheumatic adverse events
por: Zhou, Jiaxin, et al.
Publicado: (2019)